vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and TEJON RANCH CO (TRC). Click either name above to swap in a different company.

TEJON RANCH CO is the larger business by last-quarter revenue ($21.1M vs $19.6M, roughly 1.1× STANDARD BIOTOOLS INC.). TEJON RANCH CO runs the higher net margin — 7.5% vs -177.4%, a 184.9% gap on every dollar of revenue. On growth, TEJON RANCH CO posted the faster year-over-year revenue change (17.7% vs -11.5%). Over the past eight quarters, TEJON RANCH CO's revenue compounded faster (68.8% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Tejon Ranch Company, based in Lebec, California, is one of the largest private landowners in California. The company was incorporated in 1936 to organize the ownership of a large tract of land that was consolidated from four Mexican land grants acquired in the 1850s and 1860s by ranch founder Edward Fitzgerald Beale.

LAB vs TRC — Head-to-Head

Bigger by revenue
TRC
TRC
1.1× larger
TRC
$21.1M
$19.6M
LAB
Growing faster (revenue YoY)
TRC
TRC
+29.2% gap
TRC
17.7%
-11.5%
LAB
Higher net margin
TRC
TRC
184.9% more per $
TRC
7.5%
-177.4%
LAB
Faster 2-yr revenue CAGR
TRC
TRC
Annualised
TRC
68.8%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
TRC
TRC
Revenue
$19.6M
$21.1M
Net Profit
$-34.7M
$1.6M
Gross Margin
48.5%
30.6%
Operating Margin
-168.5%
10.9%
Net Margin
-177.4%
7.5%
Revenue YoY
-11.5%
17.7%
Net Profit YoY
-28.8%
-64.7%
EPS (diluted)
$-0.09
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
TRC
TRC
Q4 25
$21.1M
Q3 25
$19.6M
$12.0M
Q2 25
$21.8M
$8.3M
Q1 25
$40.8M
$8.2M
Q4 24
$17.9M
Q3 24
$22.1M
$10.9M
Q2 24
$22.5M
$5.7M
Q1 24
$45.5M
$7.4M
Net Profit
LAB
LAB
TRC
TRC
Q4 25
$1.6M
Q3 25
$-34.7M
$1.7M
Q2 25
$-33.5M
$-1.7M
Q1 25
$-26.0M
$-1.5M
Q4 24
$4.5M
Q3 24
$-26.9M
$-1.8M
Q2 24
$-45.7M
$957.0K
Q1 24
$-32.2M
$-914.0K
Gross Margin
LAB
LAB
TRC
TRC
Q4 25
30.6%
Q3 25
48.5%
28.4%
Q2 25
48.8%
40.9%
Q1 25
48.4%
15.0%
Q4 24
42.9%
Q3 24
54.9%
22.9%
Q2 24
46.1%
45.3%
Q1 24
53.1%
0.3%
Operating Margin
LAB
LAB
TRC
TRC
Q4 25
10.9%
Q3 25
-168.5%
-16.9%
Q2 25
-118.1%
-48.8%
Q1 25
-80.8%
-50.7%
Q4 24
11.9%
Q3 24
-120.9%
-34.9%
Q2 24
-134.5%
-62.4%
Q1 24
-132.2%
-53.8%
Net Margin
LAB
LAB
TRC
TRC
Q4 25
7.5%
Q3 25
-177.4%
14.0%
Q2 25
-153.7%
-20.6%
Q1 25
-63.8%
-17.8%
Q4 24
25.0%
Q3 24
-122.0%
-16.9%
Q2 24
-203.3%
16.8%
Q1 24
-70.6%
-12.3%
EPS (diluted)
LAB
LAB
TRC
TRC
Q4 25
$0.05
Q3 25
$-0.09
$0.06
Q2 25
$-0.09
$-0.06
Q1 25
$-0.07
$-0.05
Q4 24
$0.16
Q3 24
$-0.07
$-0.07
Q2 24
$-0.12
$0.04
Q1 24
$-0.27
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
TRC
TRC
Cash + ST InvestmentsLiquidity on hand
$129.4M
$9.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$399.7M
$475.2M
Total Assets
$539.6M
$630.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
TRC
TRC
Q4 25
$9.5M
Q3 25
$129.4M
$3.6M
Q2 25
$158.6M
$2.5M
Q1 25
$150.9M
$12.3M
Q4 24
$39.3M
Q3 24
$210.6M
$27.4M
Q2 24
$269.8M
$33.0M
Q1 24
$287.1M
$35.6M
Total Debt
LAB
LAB
TRC
TRC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
TRC
TRC
Q4 25
$475.2M
Q3 25
$399.7M
$473.2M
Q2 25
$424.5M
$471.5M
Q1 25
$454.6M
$472.5M
Q4 24
$473.6M
Q3 24
$489.3M
$468.3M
Q2 24
$510.3M
$469.2M
Q1 24
$577.3M
$467.4M
Total Assets
LAB
LAB
TRC
TRC
Q4 25
$630.5M
Q3 25
$539.6M
$629.6M
Q2 25
$557.0M
$618.5M
Q1 25
$579.6M
$614.6M
Q4 24
$608.0M
Q3 24
$681.5M
$598.0M
Q2 24
$708.7M
$590.8M
Q1 24
$777.7M
$581.6M
Debt / Equity
LAB
LAB
TRC
TRC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
TRC
TRC
Operating Cash FlowLast quarter
$-22.2M
$6.1M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
3.88×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
TRC
TRC
Q4 25
$6.1M
Q3 25
$-22.2M
$-2.4M
Q2 25
$-20.7M
$-381.0K
Q1 25
$-30.3M
$-1.3M
Q4 24
$14.3M
Q3 24
$-27.9M
$2.1M
Q2 24
$-39.0M
$-1.8M
Q1 24
$-62.5M
$777.0K
Free Cash Flow
LAB
LAB
TRC
TRC
Q4 25
Q3 25
$-23.1M
$-14.6M
Q2 25
$-22.6M
$-20.0M
Q1 25
$-35.3M
$-18.9M
Q4 24
$-42.9M
Q3 24
$-30.1M
$-16.8M
Q2 24
$-41.0M
$-15.8M
Q1 24
$-63.3M
$-7.3M
FCF Margin
LAB
LAB
TRC
TRC
Q4 25
Q3 25
-118.1%
-122.2%
Q2 25
-103.6%
-240.6%
Q1 25
-86.6%
-230.1%
Q4 24
-239.3%
Q3 24
-136.4%
-155.2%
Q2 24
-182.2%
-277.2%
Q1 24
-138.9%
-99.0%
Capex Intensity
LAB
LAB
TRC
TRC
Q4 25
Q3 25
4.5%
102.3%
Q2 25
8.7%
236.0%
Q1 25
12.4%
213.7%
Q4 24
319.1%
Q3 24
10.2%
174.3%
Q2 24
8.6%
245.5%
Q1 24
1.7%
109.5%
Cash Conversion
LAB
LAB
TRC
TRC
Q4 25
3.88×
Q3 25
-1.43×
Q2 25
Q1 25
Q4 24
3.19×
Q3 24
Q2 24
-1.88×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

TRC
TRC

Segment breakdown not available.

Related Comparisons